How do you decide which patients should pursue add-on bepirovirsen rather than continue indefinite nucleos(t)ide analogue monotherapy for noncirrhotic chronic HBV?

1. HBsAg quantitation to determine if they meet criteria
2. Frank discussion that only 1 in 5 patients succeed and that the 6-month weekly injections do have a relatively high rate of significant adverse hematological and renal complications requiring close laboratory monitoring.

So far, most patients have declined to consider it, given the safety and simplicity of oral therapy.